September 29, 2013

Boehringer Ingelheim Introduces FLEXcombo® 250 Doses HSB Swine Vaccine

Circovirus and M. hyo vaccine package features a larger M. hyo bottle for easier mixing

Boehringer Ingelheim Vetmedica, Inc. (BIVI), has made it easier to vaccinate swine against porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae, two of the most economically important swine diseases, in a single injection with FLEXcombo®.

    Because every swine herd is unique, FLEXcombo, one of the products in the FLEX Family of vaccines, allows producers and veterinarians to customize vaccination programs based on their specific disease problems and management protocols. Each FLEXcombo package contains a 250-mL bottle of Ingelvac CircoFLEX® and 250 mL of Ingelvac MycoFLEX® vaccine in a 500-mL headspace bottle for mixing. This provides a total of 500 mL of the mixed vaccine, enough to vaccinate 250 head with a single 2-mL injection.

    According to Sarah Jorgensen, FLEX brand manager for the BIVI Swine Division, the new FLEXcombo package makes it practical for veterinarians and producers to mix and administer the vaccine to pigs three weeks of age and older to protect against PCV2 and mycoplasma hyopneumoniae in a single injection. “We’ve focused on ease of use for customers to mix and administer Ingelvac CircoFLEX and Ingelvac MycoFLEX vaccines,” Jorgensen explains. “It’s a simple process: Aseptically, add the contents of the green-capped Ingelvac CircoFLEX bottle to the red-capped Ingelvac MycoFLEX headspace bottle, shake well and inject.”

    “Because both FLEX vaccines contain ImpranFLEX® adjuvant technology, they are highly compatible when mixed and administered, providing a rapid, long-lasting immune response with low risk of adverse reactions,” says Jorgensen. “Plus, the 250-dose package size of FLEXcombo makes it more convenient for larger production facilities to vaccinate pigs with fewer vaccine bottles and less mixing.”

    The single 2-mL injection of FLEXcombo gives producers the ability to reduce stress on both pigs and people while decreasing labor costs. Additionally, a reduced number of injections offers greater Pork Quality Assurance (PQA) benefits.

   “Since Ingelvac CircoFLEX and Ingelvac MycoFLEX were approved for use more than four years ago, well over a billion pigs have been effectively vaccinated,” Jorgensen says. “In hundreds of production facilities and in ongoing field trials, the FLEX Family of vaccines continues to provide long-lasting efficacy and safety in every dose administered to healthy, susceptible pigs.”

    For more information about FLEXcombo, contact your veterinarian, visit or call BIVI at 800-325-9167.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

For more information please visit